(160) revealed that Axitinib showed promising and tolerable clinical efficacy in individuals with hepatocellular carcinoma (HCC) who had previously received VEGF inhibitors during the advanced stages of their illness. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.